Patents Examined by Taofiq A. Solola
  • Therapies for treating and preventing chronic rhinosinusitis
    Patent number: 11413297
    Abstract: The invention provides compositions and methods for disrupting preformed bacterial biofilm or preventing formation of bacterial biofilm. Also provided in the invention are methods and compositions for treating and preventing chronic rhinosinusitis. Such compositions and methods utilize one or more antibiotic compounds in combination with at least one phospholipid compound described herein.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 16, 2022
    Assignees: AVANTI POLAR LIPIDS, LLC, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Charles G. Cochrane, Ronald A. Simon, Stephen W. Burgess, Walter A. Shaw
  • Method of treating amyotrophic lateral sclerosis with pridopidine
    Patent number: 11406625
    Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 9, 2022
    Assignee: Prilenia Neurotherapeutics Ltd.
    Inventors: Michal Geva, Ralph Laufer, Michael Hayden, Neta Zach
  • Tricyclic compounds, compositions and medicinal applications thereof
    Patent number: 11407758
    Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III).
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: August 9, 2022
    Assignee: IMPETIS BIOSCIENCES LTD.
    Inventors: Sujay Basu, Sachin Thorat, Yogesh Shejul, Anil Panmand, Meena Patel, Goraksha Khose, Rajesh Bonagiri, Dinesh Barawkar, Bheemashankar Kulkarni, Kasim Mookhtiar
  • Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
    Patent number: 11406627
    Abstract: The present invention relates to a pharmaceutical combination comprising (a) an MDM2 inhibitor and (b) an ERK inhibitor, for use in the treatment of a cancer. This invention relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination; and kits and/or packages containing such combinations.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: August 9, 2022
    Assignee: NOVARTIS AG
    Inventors: Giordano Caponigro, Ensar Halilovic, Kelli-Ann Monaco
  • Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
    Patent number: 11401257
    Abstract: Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: August 2, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Paul F. Fernandez, Antonio C. Ferretti, Ying Li, Weihong Zhang
  • Preparation of halogen analogs of picloram
    Patent number: 11401242
    Abstract: Methods for preparing 5-fluoro-6-(bromo or chloro)picloram analogs, or derivatives thereof, from picloram acid, picloram ester, or the nitrile analog of picloram are provided. The methods include chemical process steps that: (1) introduce a phthaloyl group onto the 4-amino substituent of picloram acid, picloram ester, or the nitrile analog of picloram, (2) add 2 fluorine atoms at the 5,6-positions of the pyridine ring using halex fluorination chemistry, (3) remove the phthaloyl group, hydrolyze the ester or nitrile substituent, and add chlorine or bromine to the 6-position by treatment with an acid and water, and finally, (4) esterify the 5-fluoro-6-(bromo or chloro)picloram acid produced in step (3) to a 5-fluoro-6-(bromo or chloro)picloram ester.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: August 2, 2022
    Assignee: Corteva Agriscience LLC
    Inventors: Jayachandran Devaraj, Nugzar Ghavtadze, Nicholas M. Irvine, Jeremy Kister, Melissa Lee, Ronald B. Leng, Rongrong [Mandy] Lin, Rong Ling, Noormohamed M. Niyaz, Abraham D. Schuitman, Aaron A. Shinkle, Siyu Tu, Gregory T. Whiteker, Chunming Zhang
  • Macrocyclic indole derivatives
    Patent number: 11401278
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: August 2, 2022
    Assignees: The Broad Institute, Inc., Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Laura Furst, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven J. Ferrara, Guo Wei, Patrick R. McCarren, Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Mönning, Katrin Nowak-Reppel
  • Microbiocidal picolinamide derivatives
    Patent number: 11395489
    Abstract: Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: July 26, 2022
    Assignee: Syngenta Participations AG
    Inventors: Stefano Rendine, Clemens Lamberth, Renaud Beaudegnies, Mattia Riccardo Monaco
  • Salts of a compound and the crystalline forms thereof
    Patent number: 11396507
    Abstract: The present invention belongs to the pharmaceutical field, and provides the pharmaceutically acceptable salts of the compound (S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine and the crystalline forms thereof, the solvates and the crystalline forms thereof, the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 26, 2022
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Ling Feng
  • Compounds and forms of treatment for female sexual disorders
    Patent number: 11395814
    Abstract: The invention provides safe and efficacious treatments for Female Sexual Disorders, genitopelvic pain/penetration disorders; vulvovaginal atrophy, vestibulodynia, dyspareunia, sexual interest/arousal disorder, low female libido, and female orgasmic disorder.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: July 26, 2022
    Inventor: Wendy Anne Epstein
  • System for filtering organic compounds
    Patent number: 11389749
    Abstract: A system for removing undesirable organic compounds so that the desirable cannabinoids, terpenes, and any other beneficial organic compounds can be easily and effectively captured is provided herein. The system makes use of diatomaceous earth filters through which a solution containing the organic compounds is rinsed with liquid non-polar solvent. The undesirable components remain in the diatomaceous while the beneficial organic compounds pass through and are collected in a liquid solution.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: July 19, 2022
    Inventor: Caleb Mata
  • Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
    Patent number: 11390617
    Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: July 19, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Maria Soraya Carrancio Anton, Tonia J. Buchholz, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
  • Methods and processes for the preparation of KDM1A inhibitors
    Patent number: 11390590
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: July 19, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Arthur Glenn Romero, John M. McCall, Toni Chancellor, Jian-Xie Chen, Xuemei Chen, He Zhao, Betina Biolatto, Elisabeth C. A. Brot, Zhihua Li, Xiaoming Liao
  • Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
    Patent number: 11390624
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: July 19, 2022
    Assignee: Incyte Corporation
    Inventors: Taisheng Huang, Xiaozhao Wang
  • Apelin receptor agonists and methods of use
    Patent number: 11390616
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 19, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wei Meng, Hannguang J. Chao, Heather Finlay, R. Michael Lawrence, Michael C. Myers
  • Pharmaceutical composition
    Patent number: 11376328
    Abstract: Provided is a pharmaceutical composition in which the solubility and/or dissolution properties of a poorly-soluble drug can be improved. The pharmaceutical composition comprises a poorly-soluble drug, and polyvinyl alcohol having a saponification degree of 63 mol % or more and 67 mol % or less.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 5, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Takatsune Yoshida, Hiroyuki Kojima, Yoshiaki Umemoto, Sachie Namiki, Akira Takagi, Ken Shimada
  • Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment
    Patent number: 11376264
    Abstract: Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: July 5, 2022
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Zong Wei, Annette Atkins, Ruth T. Yu
  • Atypical inhibitors of monoamine transporters; method of making; and use thereof
    Patent number: 11365195
    Abstract: Disclosed herein are a series of modafinil analogue compounds that bind with moderate to high affinity to the dopamine (DA) transporter (DAT) and several analogues also having affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. Employing aminopiperidine, piperidineamino, spirobicyclodiaza, or substituted piperazine functional groups, desired dopamine transporter affinity has been retained along with improved metabolic stability over unsubstituted piperazine ring analogues. Importantly, these compounds have no predicted addictive liability. Also disclosed are methods for treating substance use disorders as well as other neuropsychiatric disorders such as ADHD, depression, narcolepsy, and cognitive impairment.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: June 21, 2022
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Amy Hauck Newman, JoLynn Barbara Giancola, Rachel D. Slack
  • EGFR dimer disruptors and use of the same
    Patent number: 11358965
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 14, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • Compositions and methods for treating cancer
    Patent number: 11357766
    Abstract: The present invention includes composition and methods for treating cancers comprising administering to a subject a pharmaceutical composition comprising Pimavanserin or derivatives thereof in an amount sufficient to treat the reproductive cancer in the subject and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 14, 2022
    Assignee: Texas Tech University System
    Inventors: Sanjay K. Srivastava, Sharavan Ramachandran